Literature DB >> 3922829

Effects of a fructose-rich diet and the aldose reductase inhibitor, ONO-2235, on the development of diabetic neuropathy in streptozotocin-treated rats.

N Hotta, H Kakuta, H Fukasawa, M Kimura, N Koh, M Iida, H Terashima, T Morimura, N Sakamoto.   

Abstract

Streptozotocin-diabetic rats were maintained on a 72% fructose diet for 4 weeks and some were treated with an aldose reductase inhibitor (either alrestatin: 0.9 g . kg-1 . day-1 or ONO-2235: 50 mg . kg-1 . day-1). Fructose feeding significantly influenced the development of impaired motor nerve conduction velocity in the diabetic rats and this effect was positively correlated with sorbitol accumulation in the sciatic nerve of diabetic rats maintained on a fructose-rich diet. Treatment with ONO-2235, a new aldose reductase inhibitor, prevented both slowing of motor nerve conduction velocity and elevation of nerve sorbitol concentration. On the other hand, erythrocyte sorbitol levels were significantly correlated to those of the sciatic nerve (r = 0.86, p less than 0.001) and the retina (r = 0.91, p less than 0.001) in these animals. Thus, our findings suggest that increased polyol pathway activity may be related to the pathogenesis of diabetic neuropathy and erythrocyte sorbitol concentrations may prove a useful indicator for the presence of diabetic complications.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922829     DOI: 10.1007/bf00273868

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  20 in total

1.  Peripheral nerves in early experimental diabetes: expansion of the endoneurial space as a cause of increased water content.

Authors:  J Jakobsen
Journal:  Diabetologia       Date:  1978-02       Impact factor: 10.122

Review 2.  Diabetic neuropathy--new concepts of its etiology.

Authors:  R S Clements
Journal:  Diabetes       Date:  1979-06       Impact factor: 9.461

3.  Serial in vivo determinations of nerve conduction velocity in rat tails. Physiological and pathological changes.

Authors:  T Miyoshi; I Goto
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1973-08

Review 4.  The sorbitol pathway and the complications of diabetes.

Authors:  K H Gabbay
Journal:  N Engl J Med       Date:  1973-04-19       Impact factor: 91.245

5.  Glucose utilization by the polyol pathway in human erythrocytes.

Authors:  A D Morrison; R S Clements; S B Travis; F Oski; A I Winegrad
Journal:  Biochem Biophys Res Commun       Date:  1970-07-13       Impact factor: 3.575

6.  Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.

Authors:  J H Mayer; D R Tomlinson
Journal:  Diabetologia       Date:  1983-11       Impact factor: 10.122

7.  Reversal, by treatment with an aldose reductase inhibitor, of impaired axonal transport and motor nerve conduction velocity in experimental diabetes mellitus.

Authors:  D R Tomlinson; P R Holmes; J H Mayer
Journal:  Neurosci Lett       Date:  1982-08-16       Impact factor: 3.046

Review 8.  Hyperglycemia, polyol metabolism, and complications of diabetes mellitus.

Authors:  K H Gabbay
Journal:  Annu Rev Med       Date:  1975       Impact factor: 13.739

9.  Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.

Authors:  K R Gillon; J N Hawthorne; D R Tomlinson
Journal:  Diabetologia       Date:  1983-10       Impact factor: 10.122

10.  The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.

Authors:  D K Yue; M A Hanwell; P M Satchell; J R Turtle
Journal:  Diabetes       Date:  1982-09       Impact factor: 9.461

View more
  7 in total

Review 1.  Aldose reductase inhibitors and late complications of diabetes.

Authors:  P Benfield
Journal:  Drugs       Date:  1986       Impact factor: 9.546

2.  Human erythrocyte sorbitol metabolism and the role of sorbitol dehydrogenase.

Authors:  Y Nagasaka; S Fujii; T Kaneko
Journal:  Diabetologia       Date:  1988-10       Impact factor: 10.122

3.  Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235.

Authors:  H Fujishima; K Tsubota
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

4.  Thermal stress and diabetic complications.

Authors:  Y Ohtsuka; N Yabunaka; I Watanabe; H Noro; H Fujisawa; Y Agishi
Journal:  Int J Biometeorol       Date:  1995-01       Impact factor: 3.787

Review 5.  Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.

Authors:  J W Steele; D Faulds; K L Goa
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

6.  Effects of propionyl-L-carnitine and insulin on the electroretinogram, nerve conduction and nerve blood flow in rats with streptozotocin-induced diabetes.

Authors:  N Hotta; N Koh; F Sakakibara; J Nakamura; Y Hamara; T Hara; E Nakashima; H Sasaki; H Fukasawa; H Kakuta; N Sakamoto
Journal:  Pflugers Arch       Date:  1996-02       Impact factor: 3.657

7.  Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: an Indian perspective.

Authors:  S R Sharma; Nalini Sharma
Journal:  Ann Indian Acad Neurol       Date:  2008-10       Impact factor: 1.383

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.